ArticleVaccines2022

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.

Ivan Gentile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.